DarioHealth Q2 2024 GAAP EPS $0.08 Beats $(0.56) Estimate, Sales $6.255M Miss $7.914M Estimate
Portfolio Pulse from Benzinga Newsdesk
DarioHealth reported its Q2 2024 financial results, with GAAP EPS of $0.08, beating the estimate of $(0.56). However, sales were $6.255 million, missing the estimate of $7.914 million.
August 08, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
DarioHealth's Q2 2024 GAAP EPS of $0.08 beat the estimate of $(0.56), but sales of $6.255 million missed the $7.914 million estimate. This mixed result may lead to short-term volatility in the stock price.
The positive EPS surprise is a significant beat, which is generally favorable for the stock. However, the sales miss is a concern and could offset some of the positive sentiment. This mixed result is likely to cause short-term volatility in DRIO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100